The paper by Rizk et al., "Tecovirimat and mpox: A regulatory balancing act between hope, hurdles, and high-risk populations," presents a detailed discussion on the antiviral Tecovirimat (TPOXX) and its role in the treatment of mpox (formerly known as monkeypox), particularly in the context of regulatory decision-making across different countries [1]. While the authors provide a strong overview of the scientific and regulatory landscape [1], there are biases, potential confounders, misleading concepts, and flaws that warrant further examination, alongside the paper's strengths and weaknesses.
